Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 vaccine candidates in rapid development.
Hum Vaccin Immunother. 2021 03 04; 17(3):644-653.HV

Abstract

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading globally. The scientific community is attempting to procure an effective treatment and prevention strategy for COVID-19. A rising number of vaccines for COVID-19 are being developed at an unprecedented speed. Development platforms include traditional inactivated or live attenuated virus vaccines, DNA or RNA vaccines, recombinant viral vector vaccines, and protein or peptide subunit vaccines. There are 23 vaccines in the clinical evaluation stage and at least 140 candidate vaccines in preclinical evaluation. In this review, we describe research regarding basic knowledge on the virus, updates on the animal models, current landscape of vaccines in clinical evaluation and updated research results on vaccine development. Safe and effective COVID-19 vaccines require further investigation.

Links

PMC Free PDF

Authors+Show Affiliations

Li L
Henan Neurodevelopment Engineering Research Center for Children, Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China. Departments of Neonatology, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Guo P
Henan Neurodevelopment Engineering Research Center for Children, Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Zhang X
Henan Neurodevelopment Engineering Research Center for Children, Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Yu Z
Henan Neurodevelopment Engineering Research Center for Children, Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Zhang W
Henan Neurodevelopment Engineering Research Center for Children, Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Sun H
Departments of Neonatology, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.

MeSH

AnimalsCOVID-19COVID-19 VaccinesHumansPandemicsSARS-CoV-2

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33121319

Citation

Li, Lifeng, et al. "SARS-CoV-2 Vaccine Candidates in Rapid Development." Human Vaccines & Immunotherapeutics, vol. 17, no. 3, 2021, pp. 644-653.
Li L, Guo P, Zhang X, et al. SARS-CoV-2 vaccine candidates in rapid development. Hum Vaccin Immunother. 2021;17(3):644-653.
Li, L., Guo, P., Zhang, X., Yu, Z., Zhang, W., & Sun, H. (2021). SARS-CoV-2 vaccine candidates in rapid development. Human Vaccines & Immunotherapeutics, 17(3), 644-653. https://doi.org/10.1080/21645515.2020.1804777
Li L, et al. SARS-CoV-2 Vaccine Candidates in Rapid Development. Hum Vaccin Immunother. 2021 03 4;17(3):644-653. PubMed PMID: 33121319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 vaccine candidates in rapid development. AU - Li,Lifeng, AU - Guo,Pengbo, AU - Zhang,Xiaoman, AU - Yu,Zhidan, AU - Zhang,Wancun, AU - Sun,Huiqing, Y1 - 2020/10/29/ PY - 2020/10/31/pubmed PY - 2021/4/2/medline PY - 2020/10/30/entrez KW - COVID-19 pandemic KW - SARS-CoV-2 KW - animal models KW - coronavirus KW - vaccine development SP - 644 EP - 653 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 17 IS - 3 N2 - The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading globally. The scientific community is attempting to procure an effective treatment and prevention strategy for COVID-19. A rising number of vaccines for COVID-19 are being developed at an unprecedented speed. Development platforms include traditional inactivated or live attenuated virus vaccines, DNA or RNA vaccines, recombinant viral vector vaccines, and protein or peptide subunit vaccines. There are 23 vaccines in the clinical evaluation stage and at least 140 candidate vaccines in preclinical evaluation. In this review, we describe research regarding basic knowledge on the virus, updates on the animal models, current landscape of vaccines in clinical evaluation and updated research results on vaccine development. Safe and effective COVID-19 vaccines require further investigation. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/33121319/SARS_CoV_2_vaccine_candidates_in_rapid_development_ DB - PRIME DP - Unbound Medicine ER -